详情页

当前位置：首页 > 详情页

Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: An open-label, multicenter phase II study

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：

机构： [1]Gynecology, Fudan University Shanghai Cancer Center, Shanghai, China [2]Departmentof Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing CancerInstitute & Chongqing Cancer Hospital, Chongqing, China [3]Gynecology, Qilu Hospitalof Shandong University, Jinan, China [4]Department of Gynecological Oncology, PekingUniversity School of Oncology, Beijing Cancer Hospital, Beijing Institute for CancerResearch, Beijing, China [5]Oncology, Nanjing Drum Tower Hospital, Nanjing, China [6]Oncology, Jiangxi Maternal and Child Health Hospital, Nanchang, China [7]Departmentof Gynecology, Harbin Medical University Cancer Hospital, Harbin, China [8]Gynecology,Henan Cancer Hospital, Zhengzhou, China [9]Gynecology, The First AffiliatedHospital of Zhengzhou University, Zhengzhou, China [10]Department of GynecologicOncology, Zhejiang Cancer Hospital, Hangzhou, China [11]Gynecology, The Obstetrics &Gynecology Hospital of Fudan University, Shanghai, China [12]Oncology, Jiangsu HengruiPharmaceutical Co., Ltd., Beijing, China [13]Clinical Research and Development,Jiangsu Hengrui Medicine Co., Ltd., Shanghai, China [14]Department of GynecologicOncology, Fudan University Shanghai Cancer Center, Shanghai, China

出处：

DOI：

ISSN：

基金：

语种：

被引次数：

WOS：

中科院分区：

出版当年[2020]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2020]版：

Q1 ONCOLOGY

最新[2024]版：

Q1 ONCOLOGY

影响因子： 65.4 最新[2024版] 46.8 最新五年平均 32.976 出版当年[2020版] 22.846 出版当年五年平均 18.274 出版前一年[2019版] 51.769 出版后一年[2021版]

第一作者：

第一作者机构： [1]Gynecology, Fudan University Shanghai Cancer Center, Shanghai, China

推荐引用方式(GB/T 7714)：

APA：

MLA：